Key result
Early-onset HCM mutations D239N and H251N increase myosin motor function up to ~90% vs wild-type.
Population
Human β-cardiac myosin
Comparison
Early-onset hypertrophic cardiomyopathy… vs Wild-type human β-cardiac myosin
Design
Preclinical
Authors
Loading...
Hypercontractility may underlie early-onset HCM; hypothesis-generating for myosin-targeted therapies pending human validation.
Early-onset HCM mutations D239N and H251N lead to significant hyper-contractility by increasing fundamental biomechanical parameters of human β-cardiac myosin.
Adhikari et al. (2016) studied Hypertrophic cardiomyopathy (HCM). Early-onset HCM mutations D239N and H251N vs. Wild-type myosin was evaluated on Actin gliding velocity, intrinsic force, and ATPase activity. Early-onset HCM mutations D239N and H251N significantly increased actin gliding velocity, intrinsic force, and ATPase activity by 20%-90% compared to wild-type human β-cardiac myosin.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: